New Lung Cancer Drug Shows 70% Response Rate at ASCO 2026

Cancer patients with advanced lung cancer just got a new reason to hope.

At the American Society of Clinical Oncology conference this month, researchers revealed that Pumitamig, a new cancer drug, achieved a 70% response rate in patients with advanced lung cancer. The results hold true regardless of PD-L1 status, a protein marker that doctors typically use to predict how well patients will respond to immunotherapy.

This matters because many lung cancer treatments work differently depending on a patient's PD-L1 levels. Some patients have been left with fewer options when their PD-L1 status doesn't match available therapies. Pumitamig appears to sidestep that limitation entirely.

The drug represents years of research aimed at finding treatments that work for more patients. Advanced lung cancer remains one of the most challenging cancers to treat, making any improvement in response rates significant for patients and their families.

The Bright Side

The consistent 70% response rate across all PD-L1 levels means doctors may soon have a reliable option for patients who previously had limited choices. This could simplify treatment decisions and reduce the anxiety patients feel waiting to see if their biology matches available therapies.

The announcement at ASCO 2026 was part of a slate of positive cancer treatment updates. Oncology nurses are also receiving better training in medical cannabis discussions with patients, and new quality initiatives are reducing dangerous bloodstream infections in cancer care units.

Together, these advances paint a picture of cancer care becoming both more effective and more compassionate. Patients are gaining access to better drugs while the medical teams supporting them gain better tools and knowledge.

Cancer treatment has come remarkably far in just the past decade, with survival rates climbing and quality of life improving for many patients during treatment.